Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease

The Relationships Between Serum Sclerostin, Bone Mineral Density, and Vascular Calcification in Rheumatoid Arthritis

(2014) J. Paccou et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption–formation cycles?

(2014) R. Sapir-Koren et al.   OSTEOPOROSIS INTERNATIONAL

Relationship of Dickkopf1 (DKK1) with Cardiovascular Disease and Bone Metabolism in Caucasian Type 2 Diabetes Mellitus

(2014) Antonia Garcia-Martín et al.   PLoS One

Preliminary mechanism on the methylation modification of Dkk-1 and Dkk-3 in hepatocellular carcinoma

(2014) Libo Liang et al.   TUMOR BIOLOGY

Circulating Dickkopf‐1 in Diabetes Mellitus: Association With Platelet Activation and Effects of Improved Metabolic Control and Low‐Dose Aspirin

(2014) Stefano Lattanzio et al.   Journal of the American Heart Association

Serum Sclerostin in Alcoholics: A Pilot Study

(2013) E. González-Reimers et al.   ALCOHOL AND ALCOHOLISM

Osteocyte-derived insulin-like growth factor I is essential for determining bone mechanosensitivity

(2013) K.-H. William Lau et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study

(2013) Stergios A. Polyzos et al.   BIOMARKERS

The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women

(2013) Geeta Hampson et al.   BONE

Involvement of WNT/β-catenin Signaling in the Treatment of Osteoporosis

(2013) Maurizio Rossini et al.   CALCIFIED TISSUE INTERNATIONAL

The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus

(2013) Agostino Gaudio et al.   Diabetes & Vascular Disease Research

Extrahepatic complications of nonalcoholic fatty liver disease

(2013) Matthew J. Armstrong et al.   HEPATOLOGY

Effect of liver dysfunction on circulating sclerostin

(2013) Yumie Rhee et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Serum sclerostin levels in healthy men over 50 years of age

(2013) Harjit Pal Bhattoa et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial

(2013) Athanasios D. Anastasilakis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups

(2013) Mark M Smits et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease

(2013) Stergios A. Polyzos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver

(2013) Giovanni Musso et al.   TRENDS IN MOLECULAR MEDICINE

Role of wingless tail signaling pathway in osteoporosis

(2013) Athanasios D. Anastasilakis et al.   Current Opinion in Endocrinology Diabetes and Obesity

Review article: non-alcoholic fatty liver disease and osteoporosis - clinical and molecular crosstalk

(2012) Y. Yilmaz   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

High Circulating Sclerostin is Present in Patients with Thalassemia-associated Osteoporosis and Correlates with Bone Mineral Density

(2012) E. Voskaridou et al.   HORMONE AND METABOLIC RESEARCH

Association between Nonalcoholic Fatty Liver Disease (NAFLD) and Osteoporotic Fracture in Middle-Aged and Elderly Chinese

(2012) Mian Li et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Nonalcoholic Fatty Liver Disease

(2012) Stergios A. Polyzos et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease

(2012) Tugrul Purnak et al.   WIENER KLINISCHE WOCHENSCHRIFT

Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children

(2011) P. E. Pardee et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide

(2011) S. A. Polyzos et al.   OSTEOPOROSIS INTERNATIONAL

Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis

(2010) Judith Ertle et al.   INTERNATIONAL JOURNAL OF CANCER

Insulin receptor expression in bone

(2010) D. M. Thomas et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines

(2009) Stergios Polyzos et al.   CURRENT MOLECULAR MEDICINE

Wnt signaling in development and disease

(2009) Jennifer L. Freese et al.   NEUROBIOLOGY OF DISEASE

The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective

(2008) Mariana Lazo et al.   SEMINARS IN LIVER DISEASE